Skip to main content
Log in

An Update on the Management of Budd–Chiari Syndrome

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Budd–Chiari syndrome (BCS) is an uncommon condition, caused by obstruction to hepatic venous outflow. It is largely underdiagnosed, and a high index of suspicion is required for any patient with unexplained portal hypertension. The understanding of its etiology and pathology is improving with advances in diagnostic techniques. Recent studies reported an identifiable etiology in > 80% of cases. Myeloproliferative neoplasm (MPN) is the most common etiology, and genetic studies help in diagnosing latent MPN. Better cross-sectional imaging helps delineate the site of obstruction accurately. The majority of BCS patients are now treated by endovascular intervention and anticoagulation which have improved survival in this disease. Angioplasty of hepatic veins/inferior vena cava remains under-utilized at present. While surgical porto-systemic shunts are no longer done for BCS, liver transplantation is reserved for select indications. Some of the unresolved issues in the current management of BCS are also discussed in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Copelan A, Remer EM, Sands M, Nghiem H, Kapoor B. Diagnosis and management of Budd–Chiari syndrome: an update. Cardiovasc Intervent Radiol. 2015;38:1–12.

    PubMed  Google Scholar 

  2. Van Wettere M, Bruno O, Rautou P-E, Vilgrain V, Ronot M. Diagnosis of Budd–Chiari syndrome. Abdom Radiol. 2018;43:1896–1907.

    Google Scholar 

  3. Sarawagi R, Keshava SN, Surendrababu NRS, Zachariah UG, Eapen EC. Budd–Chiari syndrome complicating hydatid cyst of the liver managed by venoplasty and stenting. Cardiovasc Intervent Radiol. 2011;34:S202–S205.

    PubMed  Google Scholar 

  4. DeLeve LD, Valla D-C, Garcia-Tsao G. American association for the study liver diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–1764.

    CAS  PubMed  Google Scholar 

  5. Zhang W, Qi X, Zhang X, et al. Budd–Chiari syndrome in china: a systematic analysis of epidemiological features based on the Chinese literature survey. Gastroenterol Res Pract. 2015;2015:738548.

    PubMed  PubMed Central  Google Scholar 

  6. Perelló A, García-Pagán JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd–Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–139.

    PubMed  Google Scholar 

  7. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd–Chiari syndrome. Ann Intern Med. 2009;151:167–175.

    PubMed  Google Scholar 

  8. Cheng D, Xu H, Lu Z-J, et al. Clinical features and etiology of Budd–Chiari syndrome in Chinese patients: a single-center study. J Gastroenterol Hepatol. 2013;28:1061–1067.

    CAS  PubMed  Google Scholar 

  9. Qi X, Wu F, Ren W, et al. Thrombotic risk factors in Chinese Budd–Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost. 2013;109:878–884.

    CAS  PubMed  Google Scholar 

  10. Gao X, Gui E, Lu Z, et al. Risk factors of recurrence among 471 Chinese patients with Budd–Chiari syndrome. Clin Res Hepatol Gastroenterol. 2015;39:620–626.

    PubMed  Google Scholar 

  11. Eapen CE, Mammen T, Moses V, Shyamkumar NK. Changing profile of Budd–Chiari syndrome in India. Indian J Gastroenterol. 2007;26:77–81.

    CAS  PubMed  Google Scholar 

  12. Shrestha SM, Okuda K, Uchida T, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol. 1996;11:170–179.

    CAS  PubMed  Google Scholar 

  13. Eapen C, Elias E. Regional variations in hepatic vascular occlusion. Indian J Gastroenterol. 2005;24:191–192.

    CAS  PubMed  Google Scholar 

  14. Datta DV, Vashishta S, Samanta AK, Chhuttani PN. Diagnostic value of combined transhepatic venography and inferior vena cavography in chronic Budd–Chiari syndrome. Am J Dig Dis. 1978;23:1031–1041.

    CAS  PubMed  Google Scholar 

  15. Ki M, Choi HY, Kim K-A, Kim BH, Jang ES, Jeong S-H. Incidence, prevalence and complications of Budd–Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016;36:1067–1073.

    PubMed  Google Scholar 

  16. Goel A, Madhu K, Zachariah U, et al. A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. Indian J Med Res. 2013;137:922–927.

    PubMed  PubMed Central  Google Scholar 

  17. Terabayashi H, Okuda K, Nomura F, Ohnishi K, Wong P. Transformation of inferior vena caval thrombosis to membranous obstruction in a patient with the lupus anticoagulant. Gastroenterology. 1986;91:219–224.

    CAS  PubMed  Google Scholar 

  18. Valla D, Hadengue A, el Younsi M, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology. 1997;25:814–819.

    CAS  PubMed  Google Scholar 

  19. Mancuso A. The ischemic liver cirrhosis theory and its clinical implications. Med Hypotheses. 2016;94:4–6.

    CAS  PubMed  Google Scholar 

  20. Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R. Large regenerative nodules in Budd–Chiari syndrome and other vascular disorders of the liver. AJR Am J Roentgenol. 2002;178:877–883.

    PubMed  Google Scholar 

  21. Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd–Chiari syndrome: a study in 17 explanted livers. Hepatology. 2003;37:510–519.

    PubMed  Google Scholar 

  22. Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587–591.

    CAS  PubMed  Google Scholar 

  23. Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd–Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008;14:278–285.

    PubMed  PubMed Central  Google Scholar 

  24. Dayal S, Pati HP, Pande GK, Sharma MP, Saraya AK. Multilineage hemopoietic stem cell defects in Budd–Chiari syndrome. J Hepatol. 1997;26:293–297.

    CAS  PubMed  Google Scholar 

  25. Pati HP, Dayal S, Srivastava A, Pande GK, Acharya SK. Spectrum of hemostatic derangements, Budd–Chiari syndrome. Indian J Gastroenterol. 2003;22:59–60.

    PubMed  Google Scholar 

  26. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd–Chiari syndrome: a study from Western India. Hepatology. 2001;34:666–670.

    CAS  PubMed  Google Scholar 

  27. Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd–Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther. 2011;33:1087–1103.

    CAS  PubMed  Google Scholar 

  28. Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–4928.

    CAS  PubMed  Google Scholar 

  29. Xavier SG, Gadelha T, Pimenta G, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55:1770–1777. https://doi.org/10.1007/s10620-009-0933-y.

    Article  CAS  PubMed  Google Scholar 

  30. Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd–Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–1968.

    PubMed  Google Scholar 

  31. Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd–Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–827.

    PubMed  Google Scholar 

  32. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.

    CAS  PubMed  Google Scholar 

  33. Rai P, Kumar P, Mishra S, Aggarwal R. Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction. Indian J Gastroenterol. 2016;35:366–371.

    PubMed  Google Scholar 

  34. Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis. Trop Gastroenterol. 2011;32:279–284.

    PubMed  Google Scholar 

  35. Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134:82–85.

    CAS  PubMed  Google Scholar 

  36. Goulding C, Uttenthal B, Foroni L, et al. The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol. 2008;30:415–419.

    CAS  PubMed  Google Scholar 

  37. Jain A, Tibdewal P, Shukla A. Calreticulin mutations and their importance in Budd–Chiari syndrome. J Hepatol. 2017;67:1111–1112.

    CAS  PubMed  Google Scholar 

  38. Li M, De Stefano V, Song T, et al. Prevalence of CALR mutations in splanchnic vein thrombosis: a systematic review and meta-analysis. Thromb Res. 2018;167:96–103.

    CAS  PubMed  Google Scholar 

  39. Poisson J, Plessier A, Kiladjian J-J, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study. J Hepatol. 2017;67:501–507.

    CAS  PubMed  Google Scholar 

  40. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.

    PubMed  PubMed Central  Google Scholar 

  41. Kiladjian J-J, Cervantes F, Leebeek FWG, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–4929.

    CAS  PubMed  Google Scholar 

  42. Mahmoud AE, Wilde JT, Elias E. Budd–Chiari syndrome and factor V Leiden mutation. Lancet. 1995;345:526.

    CAS  PubMed  Google Scholar 

  43. Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd–Chiari syndrome. Gut. 2001;48:264–268.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Bhattacharyya M, Makharia G, Kannan M, Ahmed RPH, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd–Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol. 2004;121:844–847.

    PubMed  Google Scholar 

  45. Qi X, Stefano VD, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd–Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol. 2013;28:432–442.

    CAS  PubMed  Google Scholar 

  46. European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.

    Google Scholar 

  47. Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd–Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1801-12.e7.

    PubMed  Google Scholar 

  48. Jain A, Shukla A. Prothrombin gene mutation in Budd–Chiari syndrome—the first case report from India. Indian J Gastroenterol. 2018;37:174–175.

    PubMed  Google Scholar 

  49. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–1044.

    CAS  PubMed  Google Scholar 

  50. Ren W, Li X, Jia J, Xia Y, Hu F, Xu Z. Prevalence of Budd–Chiari syndrome during pregnancy or puerperium: a systematic review and meta-analysis. Gastroenterol Res Pract. 2015;2015:839875.

    PubMed  PubMed Central  Google Scholar 

  51. Rautou P-E, Plessier A, Bernuau J, Denninger M-H, Moucari R, Valla D. Pregnancy: a risk factor for Budd–Chiari syndrome? Gut. 2009;58:606–608.

    PubMed  Google Scholar 

  52. Pradhan MR, Patel SK, Saraf AA. Informed choice in modern contraceptive method use: pattern and predictors among young women in India. J Biosoc Sci. 2019;2019:1–14.

    Google Scholar 

  53. Shin N, Kim YH, Xu H, et al. Redefining Budd–Chiari syndrome: a systematic review. World J Hepatol. 2016;8:691–702.

    PubMed  PubMed Central  Google Scholar 

  54. Hoekstra J, Leebeek FWG, Plessier A, et al. Paroxysmal nocturnal hemoglobinuria in Budd–Chiari syndrome: findings from a cohort study. J Hepatol. 2009;51:696–706.

    CAS  PubMed  Google Scholar 

  55. Kochhar R, Masoodi I, Dutta U, et al. Celiac disease and Budd–Chiari syndrome: report of a case with review of literature. Eur J Gastroenterol Hepatol. 2009;21:1092–1094.

    PubMed  Google Scholar 

  56. Santos LB, Rigueira J, Vilas AP. Infliximab in the treatment of Budd–Chiari syndrome in Behçet’s disease. Reumatismo. 2019;71:163–165.

    CAS  PubMed  Google Scholar 

  57. Qi X, Han G, Guo X, et al. Review article: the aetiology of primary Budd–Chiari syndrome—differences between the West and China. Alimentary Pharmacol Ther. 2016;2016:44.

    Google Scholar 

  58. Valla D-C. Hepatic venous outflow tract obstruction etiopathogenesis: asia versus the West. J Gastroenterol Hepatol. 2004;19:S204–S211.

    Google Scholar 

  59. Darwish Murad S, Valla D-C, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd–Chiari syndrome. Hepatology. 2004;39:500–508.

    PubMed  Google Scholar 

  60. Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd–Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine. 1994;73:21–36.

    CAS  PubMed  Google Scholar 

  61. Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd–Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.

    CAS  PubMed  Google Scholar 

  62. Madanagopalan N, Solomon V, Jayanthi V, et al. Clinical spectrum of chronic Budd–Chiari syndrome and surgical relief for ‘coarctation’ of the inferior vena cava. J Gastroenterol Hepatol. 1986;1:359–369.

    Google Scholar 

  63. Sharma A, Goel A, Moses V, et al. Anticoagulating Budd–Chiari syndrome patients presenting with variceal bleed: a retrospective study. J Gastroenterol Hepatol. 2020;

  64. Liu L, Qi X-S, Zhao Y, Chen H, Meng X-C, Han G-H. Budd–Chiari syndrome: current perspectives and controversies. Eur Rev Med Pharmacol Sci. 2016;20:3273–3281.

    CAS  PubMed  Google Scholar 

  65. Langlet P, Escolano S, Valla D, et al. Clinicopathological forms and prognostic index in Budd–Chiari syndrome. J Hepatol. 2003;39:496–501.

    PubMed  Google Scholar 

  66. Das CJ, Soneja M, Tayal S, et al. Role of radiological imaging and interventions in management of Budd–Chiari syndrome. Clin Radiol. 2018;73:610–624.

    CAS  PubMed  Google Scholar 

  67. Bansal V, Gupta P, Sinha S, et al. Budd–Chiari syndrome: imaging review. Br J Radiol. 2018;91:20180441.

    PubMed  PubMed Central  Google Scholar 

  68. Mukund A, Pargewar SS, Desai SN, Rajesh S, Sarin SK. Changes in liver congestion in patients with Budd–Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. 2017;28:683–687.

    PubMed  Google Scholar 

  69. Brancatelli G, Vilgrain V, Federle MP, et al. Budd–Chiari syndrome: spectrum of imaging findings. AJR Am J Roentgenol. 2007;188:W168–W176.

    PubMed  Google Scholar 

  70. Garge SS, Keshava SN. Intramural inferior vena cava occlusion: the minaret sign. Egypt J Intern Med. 2016;28:131–132.

    Google Scholar 

  71. Ferral H, Behrens G, Lopera J. Budd–Chiari syndrome. AJR Am J Roentgenol. 2012;199:737–745.

    PubMed  Google Scholar 

  72. Cruite I, Tang A, Mamidipalli A, Shah A, Santillan C, Sirlin CB. Liver imaging reporting and data system: review of major imaging features. Semin Roentgenol. 2016;51:292–300.

    PubMed  Google Scholar 

  73. Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. J Magn Reson Imaging. 2010;18:421–450.

    Google Scholar 

  74. Gupta P, Bansal V, Kumar-M P, et al. Diagnostic accuracy of Doppler ultrasound, CT and MRI in Budd–Chiari syndrome: systematic review and meta-analysis. Br J Radiol. 2020;93:20190847.

    PubMed  PubMed Central  Google Scholar 

  75. Valla D-C. The diagnosis and management of the Budd–Chiari syndrome: consensus and controversies. Hepatology. 2003;38:793–803.

    PubMed  Google Scholar 

  76. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd–Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–89.

    CAS  PubMed  Google Scholar 

  77. Garcia-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd–Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–815.

    PubMed  Google Scholar 

  78. Rautou P-E, Moucari R, Escolano S, et al. Prognostic indices for Budd–Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009;104:1140–1146.

    PubMed  Google Scholar 

  79. De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–699.

    PubMed  Google Scholar 

  80. Sharma S, Kumar R, Rout G, Gamanagatti SR. Shalimar. Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome post-percutaneous endovascular intervention. J Gastroenterol Hepatol. 2020;35:654–662.

    CAS  PubMed  Google Scholar 

  81. Pieri L, Paoli C, Arena U, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92:187–195.

    CAS  PubMed  Google Scholar 

  82. Fisher NC, McCafferty I, Dolapci M, et al. Managing Budd–Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut. 1999;44:568–574.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Jagtap N, Sharma M, Singh J, et al. Budd–Chiari syndrome: outcomes of endovascular intervention—a single-center experience. Indian J Gastroenterol. 2017;36:209–216.

    PubMed  Google Scholar 

  84. Mukund A, Mittal K, Mondal A, Sarin SK. Anatomic recanalization of hepatic vein and inferior vena cava versus direct intrahepatic portosystemic shunt creation in Budd–Chiari syndrome: overall outcome and midterm transplant-free survival. J Vasc Interv Radiol. 2018;29:790–799.

    PubMed  Google Scholar 

  85. Rathod K, Deshmukh H, Shukla A, et al. Endovascular treatment of Budd–Chiari syndrome: single center experience. J Gastroenterol Hepatol. 2017;32:237–243.

    PubMed  Google Scholar 

  86. Tripathi D, Sunderraj L, Vemala V, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd–Chiari syndrome. Liver Int. 2017;37:111–120.

    PubMed  Google Scholar 

  87. Zhang W, Wang Q-Z, Chen X-W, et al. Budd–Chiari syndrome in China: a 30-year retrospective study on survival from a single center. World J Gastroenterol. 2018;24:1134–1143.

    PubMed  PubMed Central  Google Scholar 

  88. Shalimar KA, Kedia S, et al. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Aliment Pharmacol Ther. 2016;43:1154–1167.

    CAS  PubMed  Google Scholar 

  89. Bi Y, Chen H, Ding P, Zhou P, Ren J, Han X. Percutaneous transhepatic hepatic vein angioplasty in Budd–Chiari syndrome after transvenous failure. J Laparoendosc Adv Surg Tech A. 2018;28:1346–1351.

    PubMed  Google Scholar 

  90. Keshava SN, Moses V, Surendrababu NRS. Cannula-assisted and transabdominal ultrasound-guided hepatic venous recanalization in Budd–Chiari syndrome: a novel technique to avoid percutaneous transabdominal access. Cardiovasc Intervent Radiol. 2009;32:1257.

    PubMed  Google Scholar 

  91. Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome. Gut. 2006;55:878–884.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Mammen T, Keshava S, Eapen CE, et al. Intrahepatic collateral recanalization in symptomatic Budd–Chiari syndrome: a single-center experience. J Vasc Interv Radiol. 2010;21:1119–1124.

    PubMed  Google Scholar 

  93. Wang Q, Li K, He C, et al. Angioplasty with versus without routine stent placement for Budd–Chiari syndrome: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:686–697.

    PubMed  Google Scholar 

  94. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400.

    PubMed  Google Scholar 

  95. Keshava SN, Kota GK, Mammen T, et al. Direct intrahepatic cavo-portal shunts in Budd–Chiari syndrome: role of simultaneous fluoroscopy and trans-abdominal ultrasonography. Indian J Gastroenterol. 2006;25:248–250.

    PubMed  Google Scholar 

  96. Hatzidakis A, Galanakis N, Kehagias E, et al. Ultrasound-guided direct intrahepatic portosystemic shunt in patients with Budd–Chiari syndrome: short- and long-term results. Interv Med Appl Sci. 2019;9:86–93.

    Google Scholar 

  97. Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut. 2011;60:846.

    PubMed  Google Scholar 

  98. Mammen S, Keshava SN, Kattiparambil S. Acute portal vein thrombosis, no longer a contraindication for transjugular intrahepatic porto-systemic shunt (TIPS) insertion. J Clin Exp Hepatol. 2015;5:259–261.

    PubMed  Google Scholar 

  99. Ahmed M, Keshava SN, Moses V, et al. Transjugular intrahepatic portosystemic shunt through the strut of a previously placed stent: technical feasibility and long-term follow-up results. Cardiovasc Intervent Radiol. 2018;41:1794–1798.

    PubMed  Google Scholar 

  100. Tripathi D, MacNicholas R, Kothari C, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd–Chiari syndrome. Aliment Pharmacol Ther. 2014;39:864–872.

    CAS  PubMed  Google Scholar 

  101. Gp K, Ra B, Hs K. Catheter-directed thrombolysis and thrombectomy for the Budd–Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients. J Vasc Interv Radiol. 2006;17:383–387.

    Google Scholar 

  102. Clark PJ, Slaughter RE, Radford DJ. Systemic thrombolysis for acute, severe Budd–Chiari syndrome. J Thromb Thrombolysis. 2012;34:410–415.

    PubMed  Google Scholar 

  103. Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd–Chiari syndrome: a single centre experience and review of the literature. J Hepatol. 2004;40:172–180.

    CAS  PubMed  Google Scholar 

  104. Zhang Q, Xu H, Zu M, et al. Catheter-directed thrombolytic therapy combined with angioplasty for hepatic vein obstruction in Budd–Chiari syndrome complicated by thrombosis. Exp Therapeut Med. 2013;6:1015–1021.

    Google Scholar 

  105. Zhang QQ, Xu H, Zu MH, et al. Strategy and long-term outcomes of endovascular treatment for Budd–Chiari syndrome complicated by inferior vena caval thrombosis. Eur J Vasc Endovasc Surg. 2014;47:550–557.

    CAS  PubMed  Google Scholar 

  106. Hayek G, Ronot M, Plessier A, et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd–Chiari syndrome. Radiology. 2016;283:280–292.

    PubMed  Google Scholar 

  107. Klein AS, Molmenti EP. Surgical treatment of Budd–Chiari syndrome. Liver Transpl. 2003;9:891–896.

    PubMed  Google Scholar 

  108. Orloff MJ, Isenberg JI, Wheeler HO, Daily PO, Girard B. Budd–Chiari syndrome revisited: 38 years’ experience with surgical portal decompression. J Gastrointest Surg. 2012;16:286–300.

    PubMed  Google Scholar 

  109. Parekh J, Matei VM, Canas-Coto A, Friedman D, Lee WM, Acute Liver Failure Study Group. Budd–Chiari syndrome causing acute liver failure: a multicenter case series. Liver Transpl. 2017;23:135–42.

  110. Ara C, Akbulut S, Ince V, Karakas S, Baskiran A, Yilmaz S. Living donor liver transplantation for Budd–Chiari syndrome: overcoming a troublesome situation. Medicine. 2016;95:e5136.

    PubMed  PubMed Central  Google Scholar 

  111. Ulrich F, Pratschke J, Neumann U, et al. Eighteen years of liver transplantation experience in patients with advanced Budd–Chiari syndrome. Liver Transpl. 2008;14:144–150.

    PubMed  Google Scholar 

  112. Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd–Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006;44:520–528.

    PubMed  Google Scholar 

  113. O’Grady JG. Budd–Chiari syndrome and acute liver failure: a complex condition requiring a rapid response. Liver Transpl. 2017;23:133–134.

    PubMed  Google Scholar 

  114. Jayalakshmi VT, Bernal W. Update on the management of acute liver failure. Curr Opin Crit Care. 2020;26:163–170.

    PubMed  Google Scholar 

  115. Shalimar, Sharma S, Gamanagatti SR, et al. Acute-on-chronic liver failure in Budd–Chiari syndrome: profile and predictors of outcome [published online ahead of print, 01/02/2020]. Dig Dis Sci. 2020; https://doi.org/10.1007/s10620-019-06005-7.

  116. Rautou P-E, Angermayr B, Garcia-Pagan J-C, et al. Pregnancy in women with known and treated Budd–Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009;51:47–54.

    PubMed  Google Scholar 

  117. Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd–Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2013;25:830–841.

    PubMed  Google Scholar 

  118. Moucari R, Rautou P-E, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd–Chiari syndrome: characteristics and risk factors. Gut. 2008;57:828–835.

    CAS  PubMed  Google Scholar 

  119. Plessier A, Rautou P-E, Valla D-C. Management of hepatic vascular diseases. J Hepatol. 2012;1:S25–S38.

    Google Scholar 

  120. Kathuria R, Srivastava A, Yachha SK, Poddar U, Baijal SS. Budd–Chiari syndrome in children: clinical features, percutaneous radiological intervention, and outcome. Eur J Gastroenterol Hepatol. 2014;26:1030–1038.

    PubMed  Google Scholar 

  121. Meena BL, Khanna R, Sood V, et al. Budd–Chiari syndrome in children—outcome following radiological intervention. J Clin Exp Hepatol. 2018;8:S120–S121.

    Google Scholar 

  122. Shukla A, Bhatt P, Gupta DK, et al. Budd–Chiari syndrome has different presentations and disease severity during adolescence. Hepatol Int. 2018;12:560–566.

    PubMed  Google Scholar 

  123. Sharma VK, Ranade PR, Marar S, Nabi F, Nagral A. Long-term clinical outcome of Budd–Chiari syndrome in children after radiological intervention. Eur J Gastroenterol Hepatol. 2016;28:567–575.

    PubMed  Google Scholar 

  124. Zhang F, Wang C, Li Y. The outcomes of interventional treatment for Budd–Chiari syndrome: systematic review and meta-analysis. Abdom Imaging. 2015;40:601–608.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. E. Eapen.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Keshava, S.N., Eapen, A. et al. An Update on the Management of Budd–Chiari Syndrome. Dig Dis Sci 66, 1780–1790 (2021). https://doi.org/10.1007/s10620-020-06485-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06485-y

Keywords

Navigation